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Abstract: Nonapnea sleep disorders (NASDs) and associated pro-
blems, which are highly prevalent in patients with kidney diseases, are
associated with unfavorable medical sequelae. Nonetheless, whether
NASDs are associated with acute kidney injury (AKI) development has
not been thoroughly analyzed. We examined the association between
NASD and AKI.
We conducted a population-based study by using 1,000,000 repre-
sentative data from the Taiwan National Health Insurance Research
Database for the period from January 1, 2000, to December 31, 2010.
We studied the incidence and risk of AKI in 9178 newly diagnosed
NASD patients compared with 27,534 people without NASD matched
according to age, sex, index year, urbanization level, region of resi-
dence, and monthly income at a 1:3 ratio.
The NASD cohort had an adjusted hazard ratio (hazard ratio [HR];
95% confidence interval [CI]¼ 1.15–2.63) of subsequent AKI 1.74-fold
higher than that of the control cohort. Older age and type 2 diabetes
mellitus were significantly associated with an increased risk of AKI
(P< 0.05). Among different types of NASDs, patients with insomnia
had a 120% increased risk of developing AKI (95% CI¼ 1.38–3.51;
P¼ 0.001), whereas patients with other sleep disorders had a 127%
increased risk of subsequent AKI (95% CI¼ 1.07–4.80; P¼ 0.033).
Men with NASDs were at a high risk of AKI (P< 0.05).
This nationwide population-based cohort study provides evidence
that patients with NASDs are at higher risk of developing AKI than
people without NASDs.
(Medicine 95(11):e3067)
Abbreviations: AKI = acute kidney injury, BP = blood pressure,
BZD = benzodiazepine, CI = confidence interval, CKD = chronic
kidney disease, CVD = cardiovascular disease, DM = type 2
diabetes mellitus, HR = hazard ratio [HR], NASDs = nonapnea
sleep disorders, NHI = National Health Insurance, NHIRD = The
Taiwan National Health Insurance Research Database (NHIRD),
PPVs = positive predictive values.
INTRODUCTION
A cute kidney injury (AKI) is an immense clinical problembecause of its growing incidence and high mortality and
morbidity in the United States and worldwide over the past
decade.1,2 Although AKI was once considered a reversible
disease, a considerable amount of evidence has indicated that
AKI may have an unfavorable impact on subsequent renal
function and long-term prognosis.3,4 The risk factors for AKI
include old age, sepsis, hypovolemia, pre-existing chronic
kidney disease (CKD), cardiovascular disease (CVD), hyper-
tension, type 2 diabetes mellitus (DM), dementia, and can-
cer.1,5 Sleep disorders are changes in sleep patterns and habits
accompanied by several symptoms, including irritability and
fatigue during wakefulness. The estimated prevalence rate of
insomnia and sleep disorder in the general population is
20%.6 In 1 study, patients with kidney diseases had a
higher prevalence of sleep disorders and sleep-related pro-
blems compared with patients without kidney diseases.7
Among sleep disorders, sleep-related breathing disorders,
such as obstructive sleep apnea, are a well-established
risk factor for hypertension, CVD, stroke, mortality, and
CKD.8–10 However, the association between nonapnea
sleep disorders (NASDs) and AKI has not been extensively
investigated.
The Taiwan National Health Insurance Research Data-
base (NHIRD) is a national medical database containing
records on 26 million administered insurants for the period
January 2000 to December 2010. The National Health Insur-
ance (NHI) program covers health care for 99% of the popu-
lation and offers unrestricted access to any health care provider
of patients’ choice. The aim of this study was to determine the
incidence of AKI in patients with NASDs compared with
patients without NASDs.
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METHODS
Study Population
The Taiwan NHI program is a nationwide, comprehensive,
and compulsory insurance system established by the Bureau of
National Health Insurance, Department of Health in 1995. The
insurance program has contracts with 97% of Taiwan hospitals
and clinics and provides healthcare to 99% of the 23.74 million
persons in Taiwan.11 From the NHIRD, one of the largest
databases in the world, the claims data of 1 million persons,
selected systematically from the population of all insurants,
were released for research purposes. The NHIRD comprises
encrypted patient identification numbers as well as details on
inpatient orders, ambulatory care, dental services, medical
facility registries, physicians providing services, and prescribed
drugs. Diagnoses are coded according to the International
Classification of Diseases, Ninth Revision, Clinical Modifi-
cation (ICD-9-CM). This study is based in part on data from the
NHIRD provided by the Bureau of NHI (NHIRD-101-552),
Department of Health and managed by the National Health
Research Institutes. This cohort study was approved by the
Ethics Review Board of Kaohsiung Medical University
(KMUH-IRB-EXEMPT-20140059).
Study Patients
We executed a retrospective cohort study. The NASD
cohort comprised patients with newly identified sleep disorders
other than sleep apnea, including sleep disturbances and non-
organic sleep disorders diagnosed by physicians (ICD-9-CM
codes 780.5x, 307.4x, 333.94, 347, and 327.3x), as well as sleep
promoting medications,12 including benzodiazepine (BZD)
derivatives, BZD-related drugs, chlordiazepoxide, eszopiclone,
zaleplon, zolpidem, and zopiclone use before bedtime for at
least 3 months between January 1, 2000, to December 31, 2010,
according to the NHIRD records. The date of the first NASD
diagnosis was used as the index date. We excluded patients who
were younger than 18 years, had a history of AKI (ICD-9-CM
codes 580.X, 584.X, and 586), and had sleep apnea syndrome
(ICD-9-CM codes 780.51, 780.53, 780.57, and 327.23) before
the index year.13 NASDs were classified as unspecified sleep
disturbance (ICD- 9-CM code 780.50), sleep of nonorganic
origin (ICD- 9-CM code 307.4), sleep disturbance (ICD-9-CM
code 780.5), insomnia (ICD-9-CM code 780.52), unspecified
hypersomnia (ICD-9-CM code 780.54), other sleep disturbance
(ICD-9-CM code 780.59), restless legs syndrome (ICD-9-CM
code 333.94), dysfunctions associated with sleep stages or
arousal from sleep (ICD-9-CM code 780.56), circadian rhythm
sleep disorder (ICD-9-CM code 327.3x), unspecified disrup-
tions of the 24-h sleep–wake cycle (ICD- 9-CM code 780.55),
unspecified sleep-related movement disorder (ICD-9-CM code
780.58), and cataplexy and narcolepsy (ICD-9-CM code 347).
The control cohort comprised randomly selected patients with-
out a history of sleep disorders, AKI, or sleep promoting
medications use, frequency matched according to age, sex,
urbanization level, index year, monthly income, and region
of residence. A matching strategy was used to strengthen the
comparability between the NASD and control cohorts. The
index year was defined as the year of NASD diagnosis for
the NASD cohort and was used for randomly matching the
NASD patients with control patients who had outpatient visits in
the same year. Age was calculated from the date of birth to the
date of NASD diagnosis for the NASD cohort and from the date
of birth to the date of inclusion for the control cohort. For each
NASD patient, 3 patients were included in the control cohort.
The 2 cohorts were followed up until the development of AKI,
death, or the end of 2010 (Figure 1).
Outcome Measures
Patients with AKI were defined as those who received a
diagnosis coded as ICD-9-CM 580.X, 584.X, or 586 during
hospitalization or an outpatient visit at least once. The
person-years of follow-up were estimated from the index
date to AKI diagnosis; censoring because of withdrawal from
the insurance system, death during hospitalization, or loss to
follow-up; or December 31, 2010. Comorbidities examined in
our study were DM (ICD-9-CM code 250), hypertension
(ICD-9-CM codes 401–405), CVD (ICD-9-CM codes 410,
412, and 428), hyperlipidemia (ICD-9-CM code 272),
cerebrovascular diseases (ICD-9-CM codes 430–438), liver
disease (ICD-9-CM codes 571–572 and 456.0–456.2), gout
(ICD-9-CM code 274.x), CKD (ICD-9-CM codes 585–589,
250.4, 274.1, 283.11, 403.x1, 404.x2, 404.x3, 440.1, 442.1,
447.3, 572.4, 642.1x, 646.2x, and 794.4), advanced CKD
(ICD-9-CM codes for CKD with erythropoietin-stimulating
agent treatment, indicating that serum creatinine levels were
greater than 6mg/dL and hematocrit levels were <28%),14
peptic ulcer disease (ICD-9-CM codes 531, 532, and 533),
peripheral vascular disease (ICD-9-CM codes 443.9, 441.x,
785.4, and V43.4), and depression (ICD-9-CM codes 296.2
and 296.3).
VALIDATION
We validated the ICD-9-CM codes for identifying
NASDs and AKI by analyzing the medical records (charts)
of 200 patients who had 1 or more of the NASD ICD-9-CM
codes 780.52, 780.5, 780.50, 780.54, 780.55, 780.56,
780.58, and 780.59 and AKI ICD-9-CM code 580.X,
584.X, and 586 in the inpatient and outpatient claims data-
base of Kaohsiung Municipal Ta-Tung Hospital, which is a
regional teaching hospital in Taiwan, between January 2008
and December 2010. The contents of this database were
identical to those of the NHIRD. The clinical diagnoses of
NASDs were confirmed by psychiatrists and neurologists.
Clinical diagnosis of AKI was determined according to the
Acute Kidney Injury Network criteria.15 Positive predictive
values (PPVs) of both diseases were estimated. In total, 184
confirmed cases of NASDs and 192 confirmed cases of AKI
were identified. The PPVs of NASDs and AKI were 0.92 and
0.96, respectively.
Statistical Analysis
We used the independent t test, the chi-square test, or
fisher’s exact test to compare the distribution of risk factors
between the NASD and control cohorts. Crude and adjusted
hazard ratios (HRs) were calculated using Cox proportional
hazard regression models for the risk of AKI or prognosis
events. In multiple Cox proportional hazard regression, age,
sex, and past medical histories of DM, hypertension, hyperli-
pidemia, CVD, cerebrovascular disease, liver disease, gout,
obesity, and depression were adjusted. We used the Kaplan–
Meier curve to estimate the probability of AKI onset events and
used the log-rank test or Gehan–Breslow–Wilcoxon test to
identify differences among 2 or more groups. All statistics were
analyzed using SAS 9.3 software (SAS Institute, Inc, Cary, NC).
Statistical significance was set at P< 0.05.
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RESULTS
Baseline Characteristics of the Study Cohorts
During 2000 to 2010, we identified 9178 patients for the
NASD cohort and 27,534 patients for the control cohort. The
mean age was 54.99 16.28 years, and 45.1% of the patients in
the NASD cohort were men (Table 1). The distributions of age,
sex, index year, urbanization level, region of residence, and
monthly income were similar between the 2 cohorts. The
patients in the NASD cohort had a higher frequency of medical
visits during the year before the index date (P< 0.001) and were
more likely to have comorbidities including hypertension, DM,
hyperlipidemia, CVD, cerebrovascular disease, liver disease,
gout, CKD, peptic ulcer disease, peripheral vascular disease,
and depression as well as a higher Charlson comorbidity index
before the index date (P< 0.001).
Association of AKI With NASDs According to
Age, Sex, and Comorbidities
During the follow-up period, the overall incidence of AKI
was higher in the NASD cohort than in the control cohort (0.83
vs 0.43 per 10,000 person-y). After adjustment for baseline
characteristics and comorbidities, the risk of AKI was signifi-
cantly increased in the patients with NASDs (HR¼ 1.74; 95%
confidence interval [CI]¼ 1.15–2.63, P< 0.001) (Table 2). The
incidence of AKI increased with age (P< 0.001). The age-
specific relative risks of AKI were higher in older adults than in
young adults (HR¼ 3.02, 95% CI¼ 1.56–5.85, P¼ 0.001).
Patients with comorbid DM had a higher risk of AKI
(HR¼ 2.05, 95% CI¼ 1.24–3.39, P¼ 0.005).
Cumulative Incidences of AKI in the NASD and
Control Cohorts
We evaluated the cumulative incidence of AKI and deter-
mined that it was significantly higher in the NASD cohort (10-
year cumulative incidence, 0.5%; 95% CI¼ 0.36–0.64) than in
the control cohort (0.3%; 95% CI¼ 0.24–0.36) (log-rank test,
P< 0.001) (Figure 2). For men aged 365 years, the 10-year
cumulative incidence of AKI was 1.1% (HR¼ 7.73, 95% CI,
3.26–18.31, P< 0.001); for men aged <65 years, the cumu-
lative incidence of AKI was 0.5% (HR¼ 2.76, 95% CI, 1.35–
5.63, P¼ 0.005) (Table 3).
Subgroup Analysis
We also examined the association between the risk of AKI
and NASD subgroups. The risks of AKI were significantly
increased in NASD subgroups of insomnia (HR¼ 2.20, 95%CI,
1.38–3.51, P¼ 0.001) and other sleep disorders (HR¼ 2.27,
95% CI, 1.07–4.80, P¼ 0.033) (Table 4). The risk of AKI in
different patient subgroups is shown in Figure 3A and B. After
FIGURE 1. Flow diagram of patient selection.
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adjustment for variables, the risk of AKI was more prominent in
male NASD patients; aged>65 years; those living in rural area;
those living in Central part of Taiwan; those with a monthly
income between NT$15,000 and NT$30,000; and those without
comorbidities, including hypertension, DM, hyperlipidemia,
CVD, cerebrovascular disease, liver disease, gout, CKD,
advanced CKD, peripheral vascular disease, obesity, and
depression (P< 0.05) (Figure 3A and B).
Sensitivity Analysis
When alternative all-comorbidity matching was applied,
the association pattern was similar to that obtained in the
aforementioned main analyses. As shown in Supplementary
Tables 1 and 2, http://links.lww.com/MD/A770, the risk of AKI
was significant for patients with NASDs (HR¼ 1.47; 95%
CI¼ 1.21–1.79, P< 0.001).
DISCUSSION
We investigated the association between NASDs and AKI.
During the decade of observation, the patients with NASDs
were 1.74-fold more likely to develop AKI than those
without NASDs.
Sleep disorders are highly prevalent in patients with kidney
diseases.16,17 In previous studies,7,18 sleep quality and related
problems were more prevalent in patients with CKD and end-
stage renal disease. Increasing evidence indicates that sleep
disorders promote the development and exacerbate the severity
of several diseases, including DM and hypertension.19–22
TABLE 1. Demographic Characteristics of the NASD and Control Cohorts
NASD Cohort (n¼ 9178) Control Cohort (n¼ 27,534) P Value
Age (meanSD) 54.99 (16.28) 54.76 (16.34) –
240 1817 (19.8) 5471 (19.9) –
41–65 4585 (50.0) 13,782 (50.1)
>65 2776 (30.2) 8281 (30.1)
Gender (%) –
Female 5043 (54.9) 15,176 (55.1)
Male 4135 (45.1) 12,358 (44.9)
Urbanization
Urban 3173 (34.6) 9337 (33.9) 0.490
Suburban 3862 (42.1) 11,742 (42.6)
Rural 2143 (23.3) 6455 (23.4)
Region
Northern 4840 (52.7) 14,416 (52.4) 0.934
Central 2264 (24.7) 6864 (24.9)
Southern 1765 (19.2) 5328 (19.4)
Eastern 309 (3.4) 926 (3.4)
Monthly income
<15,000 3256 (35.5) 9813 (35.6) 0.650
15,000–29,999 4319 (47.1) 13,028 (47.3)
330,000 1603 (17.5) 4693 (17.0)
Visit ambulatory average frequency
MeanSD 0.68 (1.51) 0.18 (0.56) <0.001
Comorbidities (%)
Hypertension 4021 (43.8) 5252 (19.1) <0.001
DM 1715 (18.7) 2088 (7.6) <0.001
Hyperlipidemia 2232 (24.3) 2468 (9.0) <0.001
CVD 1546 (16.8) 1594 (5.8) <0.001
Cerebral vascular disease 360 (3.9) 321 (1.2) <0.001
Liver disease 1930 (21.0) 2173 (7.9) <0.001
Gout 1092 (11.9) 1219 (4.4) <0.001
Chronic kidney disease 367 (4.0) 377 (1.4) <0.001
Peptic ulcer 3023 (32.9) 3218 (11.7) <0.001
Peripheral vascular disease 311 (3.4) 323 (1.2) <0.001
Depression 1988 (21.7) 387 (1.4) <0.001
Charlson comorbidity index
MeanSD 1.75 (1.88) 0.64 (1.19) <0.001
0 2843 (31.0) 17,995 (65.4)
1 2289 (24.9) 5315 (19.3)
32 4046 (44.1) 4224 (15.3)
CVD¼ cardiovascular disease, DM¼ type 2 diabetes mellitus, NASD¼ nonapnea sleep disorder, SD¼ standard deviation.
Differences between the 2 cohorts were estimated using the independent t test or chi-square test.
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TABLE 2. Risk of AKI in the NASD Cohort Versus the Control Cohort
Crude Adjusted
HR (95% CI) P Value HR (95% CI)

P Value
NASD
No Ref. Ref.
Yes 1.83 (1.27–2.63) 0.001 1.74 (1.15–2.63) <0.001
Gender
Female Ref. Ref.
Male 0.97 (0.69–1.38) 0.875 0.91 (0.63–1.30) 0.589
Age
240 Ref. Ref.
41–65 1.86 (0.99–3.48) 0.051 1.81 (0.95–3.46) 0.072
>65 3.62 (1.95–6.71) <0.001 3.02 (1.56–5.85) 0.001
Urbanization
Rural Ref. Ref.
Suburban 1.04 (0.66–1.65) 0.867 1.27 (0.72–2.24) 0.405
Urban 1.01 (0.64–1.57) 0.983 1.10 (0.69–1.76) 0.686
Region
Northern Ref. Ref.
Central 1.12 (0.74–1.69) 0.606 1.18 (0.74–1.88) 0.494
Southern 1.19 (0.77–1.86) 0.438 1.26 (0.75–2.12) 0.381
Eastern 0.74 (0.23–2.34) 0.604 0.86 (0.26–2.87) 0.802
Monthly Income
330,000 Ref. Ref.
15,000–29,999 1.58 (0.90–2.77) 0.110 1.40 (0.77–2.54) 0.271
<15,000 1.37 (0.79–2.38) 0.263 1.26 (0.71–2.22) 0.434
Hypertension
No Ref. Ref.
Yes 1.64 (1.14–2.37) 0.008 0.70 (0.45–1.11) 0.134
DM
No Ref. Ref.
Yes 2.83 (1.87–4.29) <0.001 2.05 (1.24–3.39) 0.005
Hyperlipidemia
No Ref. Ref.
Yes 1.76 (1.13–2.75) 0.013 1.01 (0.60–1.67) 0.985
CVD
No Ref. Ref.
Yes 2.02 (1.22–3.31) 0.006 2.23 (0.99–4.98) 0.050
Cerebral vascular disease
No Ref. Ref.
Yes 3.47 (1.62–7.44) 0.001 1.18 (0.67–2.07) 0.570
Liver disease
No Ref. Ref.
Yes 1.43 (0.86–2.39) 0.171 0.99 (0.56–1.76) 0.984
Gout
No Ref. Ref.
Yes 2.23 (1.30–3.82) 0.004 1.53 (0.85–2.74) 0.153
CKD
No Ref. Ref.
Yes 3.25 (1.52–6.96) 0.002 2.19 (0.98–4.91) 0.056
Peptic ulcer
No Ref. Ref.
Yes 1.59 (1.05–2.42) 0.030 1.07 (0.67–1.70) 0.781
Peripheral vascular disease
No Ref. Ref.
Yes 2.17 (0.80–5.87) 0.128 1.25 (0.45–3.48) 0.665
Depression
No Ref Ref.
Yes 0.65 (0.27–1.60) 0.352 0.42 (0.17–1.06) 0.067
Charlson comorbidity index
0 Ref. Ref.
1 1.64 (1.06–2.55) 0.026 1.17 (0.73–1.89) 0.510
32 2.23 (1.49–3.34) <0.001 0.99 (0.53–1.77) 0.913
AKI¼ acute kidney injury, CI¼ confidence interval, CKD¼ chronic kidney disease, DM¼ type 2 diabetes mellitus, HR¼ hazard ratio,
NASD¼ nonapnea sleep disorder, Ref¼ reference.
Adjusted for age, sex, index year, urbanization level, region of residence, monthly income, ambulatory visit frequency, and comorbidities
(hypertension, DM, hyperlipidemia, CVD, cerebrovascular disease, liver disease, gout, peptic ulcer disease, peripheral vascular disease, depression).
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Because of the crucial roles of these diseases in kidney disease
development, it is rational to evaluate how sleep disorders
contribute to kidney disease development is imperative.
In the study by Huang et al23, which evaluated patients
from the NHIRD, the risk of developing CKD was significant
for patients with NASDs compared with patients without sleep
disorders. Our study group confirmed the study results
(P< 0.001) by using more strict definitions and validations.24
In the study by Gao et al25 in China, patients sleeping less per
night were associated with a higher risk of a lower glomerular
filtration rate. Sasaki et al26 observed that a short sleep duration
was associated with a significantly higher risk of CKD among
shift workers (P< 0.05). Turek et al proposed that sleep dis-
orders may be nontraditional risk factors for the development
and progression of CKD.27 Nonetheless, there is no cohort
studies exploring the association of NASDs with AKI risk.
In this study, we used a large nationwide data set to afford
considerable statistical power and to track long-time incident
AKI events.
Sleep and the circadian rhythm are biologically essential
for animals and humans. Healthy sleep is optimal in quality and
quantity. A satisfactory sleep duration can improve the general
condition including mood, daily performance, alertness, and
long-term health outcomes. However, patients with deficient
sleep quality and quantity may experience increasing glucose
intolerance and inflammation as well as an increasing blood
pressure (BP) and heart rate.19–21 Our study is consistent with
previous studies reporting that patients with NASDs and more
comorbidities, including hypertension, DM, and CKD, had a
higher risk of AKI development than that of comparison groups.
In the course of sleep, a decrease in sympathetic tone and an
increase in vagal tone cause nocturnal reduction of the BP.
When people are in a sleep-deficient condition, the activity of
the sympathetic nervous system is increased.21 Activation of the
sympathetic nervous system may be the pathogenesis of renal
hypertension and is proposed to be a risk factor for renal
function progression.28 The circadian rhythm is vital to human
homeostasis. The oscillation of the rennin–angiotensin–
aldosterone system is inflected by the rapid eye movement
(REM)–non-REM cycle and circadian rhythm.29,30 Patients
with depression who were deprived of sleep exhibited increas-
ing renin secretion and a concomitant trend of decreasing
hypothalamic-pituitary-adrenal axis activity during the recov-
ery night.31 Activating rennin–angiotensin–aldosterone system
could be another pathological mechanism of kidney disease
development. Diminishing sleep duration and quality increased
the levels of high-sensitivity C-reactive protein, white blood
cells, and proinflammatory cytokines.20,32 Ohkuma et al33
determined that the urinary albumin–creatinine ratio was
associated with sleep duration in patients with type 2 diabetes.
Inflammation causes glomerular endothelial dysfunction, which
may lead to renal function decrease. Sauvet et al34 observed
vascular dysfunction before an increase in sympathetic activity
and systolic BP under sleep deprivation.
The strength of our study is that it was designed to reduce
environmental effects, selection, and detection bias. Moreover,
the study population was well-defined and complete follow-up
because our design relied on computerized registries that pro-
vide complete nationwide coverage. Therefore, our finding of
an increased risk of AKI in patients with NASDs is robust.
TABLE 3. Risk of AKI in the Control Cohort Versus the NASD Cohort Stratified by Sex and Age
<65 Years Old 365 Years Old
No. Cases (%)
Adjusted HR
(95% CI) P Value No. Cases (%)
Adjusted HR
(95% CI)

P Value
Female
Control cohort 29 (0.3) Ref. 16 (0.4) 1.71 (0.88–3.31) 0.111
NASD cohort 21 (0.5) 1.59 (0.87–2.92) 0.134 7 (0.5) 1.27 (0.49–3.31) 0.621
Male
Control cohort 15 (0.2) Ref 7 (0.3) 1.90 (0.75–4.81) 0.177
NASD cohort 19 (0.5) 2.76 (1.35–5.63) 0.005 15 (1.1) 7.73 (3.26–18.31) <0.001
AKI¼ acute kidney injury, CI¼ confidence interval, HR¼ hazard ratio, NASD¼ nonapnea sleep disorder, Ref¼ reference.
Adjusted for age, sex, index year, urbanization level, region of residence, monthly income, ambulatory visit frequency, and comorbidities
(hypertension, DM, hyperlipidemia, CVD, cerebrovascular disease, liver disease, gout, peptic ulcer disease, peripheral vascular disease, depression).
FIGURE 2. Cumulative incidence of AKI in the NASD (dash line)
and control (solid line) cohorts. AKI¼ acute kidney injury,
NASDs¼nonapnea sleep disorders.
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LIMITATIONS
This study has several limitations. First, data on objective
sleep quality and other mental health conditions highly comor-
bid with NASDs were lacking. Second, diseases may be mis-
classified when an administrative database is used. To mitigate
this problem, we identified NASD diagnoses according to ICD-
9-CM codes and sleep promoting medications use. Moreover,
the NHI Administration of Taiwan reviews charts, audits
medical charges, and imposes heavy penalties for inappropriate
charges or malpractice to ensure the accuracy of claims. Third,
the NASD cohort had significantly more comorbidities than did
the control cohort. Hence, we performed a sensitivity test to
match the comorbidities of the 2 cohorts and still obtained a
positive result. Fourth, because of the definition of NASDs in
our cohort, the effect of sleep promoting medications use on
AKI development requires investigation. We analyzed the
dose–response relationship between sleep promoting medi-
cations use and AKI development and the result was negative.
Fifth, the NHIRD lacks information on variables that may
contribute to the risk of AKI development, namely a family
history of kidney disease, lifestyle, body weight, and laboratory
data. Thus, we could not adjust for and include these variables in
the propensity analysis, leading to a difference in the propensity
score between cohorts. Therefore, we added the Charlson
comorbidity index score to the propensity score in multivariable
and stratified analyses to control for confounders. Finally, the
NHIRD is a disconnected research database. The unknown
symptom period of NASDs may cause underestimation of
the incidence of CKD in patients with NASDs. Despite these
limitations, this nationwide population-based longitudinal
cohort study provides a valuable contribution by clarifying
the relationship between NASDs and the risk of subsequent
AKI events in an Asian population. Our findings may benefit
from further analysis regarding specific sleep disorders con-
tributing to AKI incidence in future studies.
CONCLUSION
In a Taiwanese nationwide population cohort, NASDs
were significantly associated with an increased risk of AKI,
especially in men. Because the number of patients with NASDs
is increasing, enhancing sleep disorder management may be
vital for AKI prevention.
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TABLE 4. Comparison of the Risk of AKI Among NASD Subgroups
NASD Cohort vs Control Cohort
Case Total
Per 1000
Person-Years
Crude HR
(95% CI)
Adjusted HR
(95% CI)

P Value
Control cohort 84 27534 0.43 Ref. Ref.
NASD cohort
Insomnia 28 4402 1.09 2.38 (1.55–3.66) 2.20 (1.38–3.51) 0.001
Sleep disturbance 9 3379 0.44 0.98 (0.49–1.94) 0.92 (0.45–1.89) 0.825
Other sleep disorders 8 1397 1.01 2.20 (1.06–4.54) 2.27 (1.07–4.80) 0.033
AKI¼ acute kidney injury, CI¼ confidence interval, HR¼ hazard ratio, NASD¼ nonapnea sleep disorder, Ref¼ reference.
Adjusted for age, sex, index year, urbanization level, region of residence, monthly income, ambulatory visit frequency, and comorbidities
(hypertension, DM, hyperlipidemia, CVD, cerebrovascular disease, liver disease, gout, advanced CKD, peptic ulcer disease, peripheral vascular
disease, obesity, depression).
FIGURE 3. Forest tree plot of increased HRs for AKI for (3A) baseline characteristics and (3B) comorbidities. AKI¼ acute kidney injury,
HR¼hazard ratio.
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